2021 year in review: Spotlight on eosinophils - 03/02/22

Abstract |
This review highlights recent advances in the understanding of eosinophils and eosinophilic diseases, particularly eosinophilic gastrointestinal diseases during the last year. The increasing incidence of diseases marked by eosinophilia has been documented and highlighted the need to understand eosinophil biology and eosinophilic contributions to disease. Significant insight into the nature of eosinophilic diseases has been achieved using next-generation sequencing technologies, proteomic analysis, and machine learning to analyze tissue biopsies. These technologies have elucidated mechanistic underpinnings of eosinophilic inflammation, delineated patient endotypes, and identified patient responses to therapeutic intervention. Importantly, recent clinical studies using mAbs that interfere with type 2 cytokine signaling or deplete eosinophils point to multiple and complex roles of eosinophils in tissues. Several studies identified distinct activation features of eosinophils in different tissues and disease states. The confluence of these studies supports a new paradigm of tissue-resident eosinophils that have pro- and anti-inflammatory immunomodulatory roles in allergic disease. Improved understanding of unique eosinophil activation states is now poised to identify novel therapeutic targets for eosinophilic diseases.
Le texte complet de cet article est disponible en PDF.Key words : Eosinophils, eosinophilic gastrointestinal diseases, biologics, chronic rhinosinusitis, asthma, endotypes
Abbreviations used : COVID-19, CRS, CRSwNP, EGID, EoE, EoG, RNAseq, scRNAseq
Plan
| This publication was supported in part by awards of the National Institutes of Health (AI045898, U19 AI070235, and U54 AI117804 to M.E.R.). |
|
| Disclosure of potential conflict of interest: M. E. Rothenberg is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celgene, Astra Zeneca, Adare/Ellodi Pharma, GlaxoSmithKline, Regeneron/Sanofi, Revolo Biotherapeutics, Celldex, and Guidepoint, has an equity interest in the first 5 listed, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate, and is an inventor of patents owned by Cincinnati Children’s Hospital. J. L. M. Dunn has no financial interests to disclose. |
Vol 149 - N° 2
P. 517-524 - février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
